Shares of Glenmark Pharmaceuticals Ltd were trading in the green and 1% higher on 29 April after the company announced receiving USFDA final approval for its acetaminophen and ibuprofen tablet formulations.

In its regulatory filing, the company said, “The company has received the final approval by the United States Food & Drug Administration (USFDA) for acetaminophen and ibuprofen tablets, 250 mg/125 mg (OTC), determined by the FDA to be bioequivalent to advil dual action with acetaminophen tablets, 250 mg/125 mg (OTC), of Haleon US Holdings, LLC.”

Glenmark Therapeutics Inc., USA, will distribute the 250 mg/125 mg (OTC) acetaminophen and ibuprofen pills in the US.

While 52 ANDAs are pending USFDA approval, Glenmark has officially received approval for 195 goods for distribution in the US market.

To support and accelerate the extension of its current pipeline and portfolio, Glenmark said that in addition to these internal filings, it is still searching for and looking at outside development collaborations.

On 25 April, 2024, and 26 April, 2023, respectively, the share reached its 52-week high of Rs 1,095.95 and 52-week low of Rs 516.65.

At 11:55 am, the shares of Glenmark Pharma were trading 0.38% higher at Rs 1,083.50 on NSE.